Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KCNJ6 | P48051 | 6/20 | 0.39 |
| ▸ | KCNJ3 | P48549 | 6/20 | 0.39 |
| ▸ | KCNJ5 | P48544 | 4/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3887467 | 1.00 | ALOX5 (0.45) | ALOX5CNR1ESR1HPGDKCNJ6 | |
| SCHEMBL1131500 | 0.89 | CNR1 (0.43) | CNR1ESR1HPGDKCNJ6KCNJ3 | |
| SCHEMBL1131498 | 0.89 | CNR1 (0.43) | CNR1ESR1HPGDKCNJ6KCNJ3 | |
| SCHEMBL1131971 | 0.86 | CMKLR1 (0.41) | CNR1HPGDKCNJ6KCNJ3KCNJ5 | |
| SCHEMBL1131969 | 0.86 | CMKLR1 (0.41) | CNR1HPGDKCNJ6KCNJ3KCNJ5 | |
| SCHEMBL1131504 | 0.83 | CNR1 (0.43) | CNR1ESR1HPGDKCNJ6KCNJ3 | |
| SCHEMBL1131499 | 0.79 | CNR1 (0.48) | ALOX5CNR1ESR1HPGDKCNJ6 | |
| SCHEMBL1132022 | 0.77 | CMKLR1 (0.41) | CNR1HPGDKCNJ6KCNJ3KCNJ5 | |
| SCHEMBL1132052 | 0.76 | PTGS1 (0.41) | SMN1; SMN2 | |
| SCHEMBL1131332 | 0.76 | PTGS1 (0.41) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663105-A4 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2009-04-15 | — | — | EP | disclosed |
| US-7112601-B2 | Cycloalkyl heterocycles for treating hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1663105-A2 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | Bristol-Myers Squibb Company (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005034850-A2 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050075376-A1 | Cycloalkyl heterocycles for treating Hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075376-A1 | Cycloalkyl heterocycles for treating Hepatitis C virus | HCCS, NSUN2, HAVCR2 | ALOX5 775/4885CNR1 625/4885ESR1 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.